Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript Summary
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript Summary
Strong growth in Services segment, with a revenue increase of 26% for the fiscal year.The following is a summary of the Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript:
以下是simulations plus, inc. (slp) 2024年第四季度業績會交易會議摘要：
Financial Performance:
金融業績：
Simulations Plus reported a total revenue increase of 18% to $70 million for the fiscal year.
Diluted EPS for the year was $0.49, exceeding the high-end guidance.
Strong growth in Services segment, with a revenue increase of 26% for the fiscal year.
Software revenue increased by 12% for the fiscal year, driven by major upgrades and integrations such as GPX.
Gross margin for the fiscal year was 62%, with software gross margin at 84%.
Simulations Plus報告財政年度總營業收入增長18%至$70 million。
年度攤薄後每股收益爲$0.49，超過高端預期。
服務業務板塊增長強勁，財政年度營業收入增長26%。
軟件營業收入財政年度增長12%，受GPX等主要升級和整合推動。
財政年度毛利率爲62%，軟件毛利率達到84%。
Business Progress:
業務進展：
Launched significant updates to flagship products including GastroPlus and ADMet Predictor.
Expansion of service offerings through acquisitions such as Pro-ficiency, doubling the TAM to $8 billion.
Integration of Pro-ficiency ahead of schedule, enhancing offerings along the drug development continuum.
Implemented combined go-to-market strategies for enhanced business development opportunities.
推出了對旗艦產品GastroPlus和ADMet Predictor的重大更新。
通過收購Pro-ficiency等擴大了服務業務，使目標市場提升至80億美元。
提前整合Pro-ficiency，增強了沿着藥物開發連續體的服務。
實施了綜合的市場推廣策略，提升了業務發展機會。
Opportunities:
機會：
Acquisition of Pro-ficiency significantly expands market opportunities, particularly in clinical trial operations and commercialization.
Positive initial budget discussions for 2025 indicate potential for improved client spending environment.
收購Pro-ficiency顯著擴大了市場機會，特別是在臨床試驗運營和商業化領域。
2025年初正面的預算討論顯示，客戶支出環境有望改善。
Risks:
風險：
Noted renewal slippage and softer growth in Asian markets for the software segment, expecting to address this moving forward.
注意到軟件業務領域續簽的滑坡和亞洲市場增長較弱，預計在未來解決這個問題。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
